/
Pharmaceutical preparations company · E9 · FY ends Sep · Revenue $25M · -2.25% margin · $304K FCF
The business is unprofitable at the operating level (-2.25% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 46.0% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$25M
▼ -46.0% YoY
Net Income (TTM)
-$1M
▲ +81.5% YoY
Op. Margin
-2.25%
▲ +3.4pp YoY
ROIC
-1.04%
▲ +3.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$304K
▲ +129.6% YoY
Op. Cash Flow (TTM)
$544K
▲ +74.3% YoY
Net Debt
-$10M
Net Cash Position
Cash & Equiv.
$10M
5Y CAGR: -11.4%
Continue Research